Corient Private Wealth LLC Purchases 8,894 Shares of AstraZeneca PLC (NASDAQ:AZN)

Corient Private Wealth LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 4.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 197,257 shares of the company's stock after acquiring an additional 8,894 shares during the period. Corient Private Wealth LLC's holdings in AstraZeneca were worth $12,642,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in AZN. Raymond James Financial Inc. acquired a new position in shares of AstraZeneca in the 4th quarter valued at $158,018,000. Bank of Montreal Can grew its holdings in shares of AstraZeneca by 109.6% in the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company's stock valued at $238,397,000 after buying an additional 1,605,758 shares during the period. Franklin Resources Inc. grew its holdings in shares of AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company's stock valued at $1,492,649,000 after buying an additional 1,522,715 shares during the period. Parnassus Investments LLC grew its holdings in shares of AstraZeneca by 15,819.8% in the 4th quarter. Parnassus Investments LLC now owns 1,179,018 shares of the company's stock valued at $77,249,000 after buying an additional 1,171,612 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of AstraZeneca in the 3rd quarter valued at $72,437,000. Institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Down 2.1 %

NASDAQ AZN traded down $1.59 on Friday, reaching $74.93. The company had a trading volume of 5,172,806 shares, compared to its average volume of 4,941,375. The firm has a market capitalization of $232.37 billion, a price-to-earnings ratio of 33.16, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a 1-year low of $62.75 and a 1-year high of $87.68. The company's fifty day moving average is $72.83 and its 200-day moving average is $72.00.

Remove Ads

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. On average, research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be paid a dividend of $1.03 per share. This represents a dividend yield of 2%. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date is Friday, February 21st. AstraZeneca's dividend payout ratio is currently 91.15%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating for the company. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.